MHRA: Transferring patients to the new licensed buccal midazolam preparation
13th October 2011
The UK Medicines and Healthcare Regulatory Agency (MHRA) have highlighted that care is needed on transferring patients from unlicensed buccal midazolam preparations to the new licensed buccal midazolam preparation (Buccolam, ViroPharma).
Buccolam is oral midazolam 5mg/mL provided in age-specific, individual doses of 2.5mg, 5mg, 7.5mg or 10mg, in pre-filled syringes for buccal delivery (see our news item 14-09-2011). The NHS list price of 4 dose units is £82, £85.50, £89 and £91.50 respectively. It is licensed for patients diagnosed with epilepsy from age 3months to <18years.
Buccolam is half the strength of some of the unlicensed preparations that have been used and is also a different salt; it contains the hydrochloride salt, whereas some other preparations contain the maleate salt of midazolam. MHRA state that although there is some suggestion that the maleate salt may be better absorbed in the buccal cavity, there are adequate studies with midazolam hydrochloride to support the dosing schedule authorized for Buccolam in the SPC. It also references a publication of the experience of a hospital paediatric unit transferring its patients to licensed Buccolam.
- Dexamethasone 4mg/mL injection supply problem
- NICE guideline on managing medicines in care homes
- New buprenorphine patch launched in UK
- Die Ausgabe 01/2014 des APM-Newsletter ist erschienen
- Tramadol to be a Schedule 3 CD and temazepam exemptions to be removed
- PCF4 print version now only £25!
- NICE evidence summary of oral ketamine for chronic pain
- First ever Global Atlas identifies unmet need for palliative care
- ACMD recommends reclassifying ketamine
- Phosphate enema new contra-indication